Denali Therapeutics Inc. (DNLI) Capital expenditures 2016–2025
Denali Therapeutics Inc. (DNLI) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$9.5MFY2025 · since FY2016: $6.1M → $9.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $9.5M | -40.3% |
| FY2024 | $15.9M | +23.0% |
| FY2023 | $12.9M | -27.4% |
| FY2022 | $17.8M | +109.8% |
| FY2021 | $8.5M | +174.6% |
| FY2020 | $3.1M | -82.7% |
| FY2019 | $17.9M | +428.1% |
| FY2018 | $3.4M | +18.0% |
| FY2017 | $2.9M | -53.1% |
| FY2016 | $6.1M | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice